IDRA Idera Pharmaceuticals
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Company profile
Ticker
IDRA
Exchange
Website
CEO
Vincent Milano
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Seagen ...
Former names
HYBRIDON INC
SEC CIK
Corporate docs
IRS number
43072298
IDRA stock data
()
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
23 Jun 21
44 Biggest Movers From Yesterday
23 Jun 21
12 Health Care Stocks Moving In Tuesday's After-Market Session
22 Jun 21
34 Stocks Moving In Tuesday's Mid-Day Session
22 Jun 21
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
22 Jun 21
Press releases
Thinking about buying stock in Entera Bio, Torchlight Energy, Idera Pharmaceuticals, Nikola Corp, or Orphazyme?
23 Jun 21
Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?
22 Jun 21
Idera Pharmaceuticals Announces Corporate Updates
18 May 21
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
29 Apr 21
Vyant Bio Announces Newly Appointed Board of Directors
5 Apr 21
Calendar
29 Apr 21
24 Jun 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 3.34M | 2.8M | 3.2M | 2.72M |
| Cash used (since last report) | n/a | n/a | 9.31M | 7.79M | 8.91M | 7.57M |
| Cash remaining | n/a | n/a | 35.23M | 36.75M | 35.64M | 36.97M |
| Runway (months of cash) | n/a | n/a | 10.5 | 13.1 | 11.1 | 13.6 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 Jun 21 | Soland Daniel B | Common Stock | Buy | Aquire P | No | No | 1.19 | 50,000 | 59.5K | 78,843 |
| 8 Jun 21 | Schafer Carol | Stock Option Common Stock | Grant | Aquire A | No | No | 1.31 | 26,000 | 34.06K | 26,000 |
| 8 Jun 21 | Dougherty Michael R | Stock Option Common Stock | Grant | Aquire A | No | No | 1.31 | 26,000 | 34.06K | 26,000 |
| 8 Jun 21 | Geraghty James A | Stock Option Common Stock | Grant | Aquire A | No | No | 1.31 | 26,000 | 34.06K | 26,000 |
| 8 Jun 21 | Csimma Cristina | Stock Option Common Stock | Grant | Aquire A | No | No | 1.31 | 26,000 | 34.06K | 26,000 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
57.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 61 |
| Opened positions | 20 |
| Closed positions | 15 |
| Increased positions | 19 |
| Reduced positions | 12 |
13F shares |
Current |
|---|---|
| Total value | 108.01M |
| Total shares | 28.62M |
| Total puts | 1.23M |
| Total calls | 443.1K |
| Total put/call ratio | 2.8 |
Largest owners |
Shares | Value |
|---|---|---|
| Pillar Pharmaceuticals 6 | 16.75M | $87.27M |
| Castellina Ventures | 2.18M | $7.99M |
| Baker Bros. Advisors | 2.05M | $2.66M |
| Anson Funds Management | 1.71M | $2.22M |
| Vanguard | 1.27M | $1.65M |
| Susquehanna International | 728.33K | $947K |
| BLK Blackrock | 633.44K | $823K |
| Millennium Management | 435.64K | $566K |
| Two Sigma Investments | 313.25K | $407K |
| Geode Capital Management | 258.45K | $335K |
Financial report summary
?Competition
Pfizer • Ionis Pharmaceuticals • Gilead Sciences • Astrazeneca • Dynavax Technologies • Durect • Forte Biosciences • Iovance Biotherapeutics • Chinook Therapeutics • OncoSec MedicalContent analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
accelerated, accomplishment, afford, Agency, Ataxia, attrition, behalf, budget, calendar, concept, contemporaneously, customary, cutoff, cutting, DCR, decided, departed, derecognition, derecognized, detailed, developmental, disappointing, discover, dramatically, dystrophy, effort, EMA, endpoint, European, expertise, FA, Field, fight, force, Friedreich, gene, growth, hire, hold, implement, implementation, insufficient, insurance, knowledge, launch, litigation, low, met, morale, myotonic, nominal, opportunity, organizational, package, path, pipeline, pivotal, premium, prevention, promote, proof, reallocate, replacement, Scriptr, seventy, site, spend, SPT, streamline, succeed, successful, systematic, unanticipated, unforeseen, unintended, unsuccessful, yield
Removed:
Accompanied, activation, adding, agnostic, alternative, American, anticipate, antigen, antitumor, beneath, beneficial, beneficially, Cambridge, cancel, cancellation, characterize, characterizing, close, closure, combined, complex, comprised, confirmed, consecutive, constrained, death, delivery, determinable, discovery, dividend, dose, dosed, doubt, escalation, evaluable, exceed, expansion, final, granting, IFN, improved, influence, inform, inhibitor, instrument, investor, irRC, Keytruda, lattice, Licensee, Liquidity, Merck, MHC, mitigate, modifying, modulation, Multicenter, NDA, negotiating, noting, observation, observed, optimal, pending, post, preceding, Preliminary, protocol, purpose, ranged, readily, recommended, reduce, reducing, reflective, relevant, removing, resolved, responsible, Secretary, selected, shareholder, short, signaling, Simon, sponsor, stage, statistically, sublicense, suggest, tolerability, Topic, transferred, translational, twenty, unrealized, upfront, upregulated, utilized, worldwide, written
Financial reports
10-Q
2021 Q1
Quarterly report
29 Apr 21
10-K
2020 FY
Annual report
28 Feb 21
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
30 Apr 20
10-K
2019 FY
Annual report
11 Mar 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
6 Mar 19
Current reports
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 21
8-K
Idera Pharmaceuticals Announces Corporate Updates
18 May 21
8-K
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
29 Apr 21
8-K
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of
18 Mar 21
8-K
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
1 Mar 21
8-K
Regulation FD Disclosure
13 Jan 21
8-K
Idera Pharmaceuticals to Present at Upcoming Conferences
11 Jan 21
8-K
Departure of Directors or Certain Officers
5 Jan 21
8-K
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
15 Dec 20
8-K
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
17 Nov 20
Registration and prospectus
S-3/A
Shelf registration (amended)
18 May 21
S-3
Shelf registration
2 Mar 21
424B5
Prospectus supplement for primary offering
3 Sep 20
424B5
Prospectus supplement for primary offering
2 Sep 20
S-3
Shelf registration
2 Sep 20
S-3
Shelf registration
4 Aug 20
S-3
Shelf registration
4 Aug 20
S-3
Shelf registration
2 Jun 20
424B5
Prospectus supplement for primary offering
12 May 20
S-8
Registration of securities for employees
11 Jul 19
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
1 May 20
DEF 14A
Definitive proxy
6 Apr 20
PRE 14A
Preliminary proxy
25 Mar 20
DEF 14A
Definitive proxy
25 Apr 19
DEFM14A
Proxy related to merger
30 May 18
DEF 14A
Definitive proxy
22 May 18
PRE 14A
Preliminary proxy
10 May 18
DEFM14A
Proxy related to merger
28 Mar 18
Other
EFFECT
Notice of effectiveness
26 May 21
CORRESP
Correspondence with SEC
23 May 21
EFFECT
Notice of effectiveness
3 Sep 20
CORRESP
Correspondence with SEC
30 Aug 20
EFFECT
Notice of effectiveness
17 Aug 20
CORRESP
Correspondence with SEC
11 Aug 20
UPLOAD
Letter from SEC
10 Aug 20
UPLOAD
Letter from SEC
10 Aug 20
EFFECT
Notice of effectiveness
12 Jun 20
CORRESP
Correspondence with SEC
9 Jun 20
Ownership
4
IDERA PHARMACEUTICALS / DANIEL B SOLAND ownership change
21 Jun 21
4
IDERA PHARMACEUTICALS / MAXINE GOWEN ownership change
10 Jun 21
4
IDERA PHARMACEUTICALS / MICHAEL R DOUGHERTY ownership change
10 Jun 21
4
IDERA PHARMACEUTICALS / Mark Alan Goldberg ownership change
10 Jun 21
4
IDERA PHARMACEUTICALS / JAMES A GERAGHTY ownership change
10 Jun 21
4
IDERA PHARMACEUTICALS / Cristina Csimma ownership change
10 Jun 21
4
IDERA PHARMACEUTICALS / CAROL SCHAFER ownership change
10 Jun 21
SC 13D/A
IDERA PHARMACEUTICALS / Pillar Pharmaceuticals 6 ownership change
7 Jun 21
4
IDERA PHARMACEUTICALS / MICHAEL R DOUGHERTY ownership change
3 Jun 21
4/A
IDERA PHARMACEUTICALS / YOUSSEF EL ZEIN ownership change
29 Apr 21
Patents
APP
Utility
Immune Modulation with TLR9 Agonists for Cancer Treatment
25 Feb 21
The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
APP
Utility
Immune Modulation with TLR9 Agonists for Cancer Treatment
11 Feb 21
The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
GRANT
Utility
Immune modulation with TLR9 agonists for cancer treatment
16 Nov 20
The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
GRANT
Utility
Containment of data structures with data objects in data modeling tools
26 Oct 20
A data object design system and method facilitates and generates creation of data objects to contain and, thus, contain data structures within the data objects.
GRANT
Utility
Immune modulation with TLR9 agonists for cancer treatment
14 Sep 20
The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
Transcripts
Reddit threads
IDRA the volume ?
22 Jun 21
$ADVM dropped 60% to $4 overnight due to "Severe Adverse Effects" in Clinical Trials. They used to be worth over $25.
29 Apr 21
Daily Discussion Thread - April 29th, 2021
29 Apr 21
Daily Discussion Thread - April 28th, 2021
28 Apr 21
Daily Discussion Thread - April 27th, 2021
27 Apr 21
Daily Discussion Thread - April 26th, 2021
26 Apr 21
Even More Insider Buying, and a Reason to Be Cautious, in Impac Mortage (NSYE: IMH)
18 Apr 21
Upside calls.
17 Apr 21
Let me know what stocks you want to go green and I'll sell my shares! Works every time.
9 Apr 21
$IDRA
5 Apr 21